Imaging Multidrug Resistance in Hematological Malignancies

References

• Nooter, K., Burger, H. and Stoter, G. (1996) “Multidrug resistance-associated protein (MRP) in hematologic malignancies”, Leuk. Lymphoma 20, 381–387.
   PubMed Web of Science ®Google Scholar
• Shen, D.W., Fojjo, A., Chin, J.E., et al. (1986) “Human multidrug resistant cell lines: increased MDR1 expression can precede amplification”, Science 232, 643–645.
   PubMed Web of Science ®Google Scholar
• Juliano, R.I. and Ling, V. (1976) “A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants”, Biochem. Biophys. Acta 455, 152–162.
   PubMed Web of Science ®Google Scholar
• Shen, D.W., Fojjo, A., Chin, J.E., et al. (1986) “Human multidrug resistant cell lines: increased MDR1 expression can precede amplification”, Science 232, 643–645.
   PubMed Web of Science ®Google Scholar
• Gottesman, M.M. (1993) “How cancer cells evade chemotherapy: sixteenth Richard and Hilda Rosenthal foundation award lecture”, Cancer Res. 53, 747–754.
   PubMed Web of Science ®Google Scholar
• Beck, W.T. and Dalton, W.S. (1997) In: DeVita, V.T., Hellman, S. and Rosenberg, S.A., eds, (J.B. Lippincott Co., Philadelphia), pp. 498–512.
   Google Scholar
• Lehne, G., Morkrid, L., den Boer, M. and Rugstad, H.E. (2000) “Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP)”, Int. J. Clin. Pharmacol. Ther. 38, 187–195.
   PubMed Web of Science ®Google Scholar
• Filipits, M., Stranzl, T., Pohl, G., Suchomel, R.W., Zochbauer, S., Brunner, R., Lechner, K. and Pirker, R. (1999) “MRP expression in acute myeloid leukemia. An update”, Adv. Exp. Med. Biol. 457, 141–150.
   PubMed Web of Science ®Google Scholar
• Scheffer, G.L., Wijngaard, P.L.J., Flens, M.J., et al. (1995) “The drug resistance-related protein LRP is the human major vault protein”, Nature Med. 1, 578–582.
   PubMed Web of Science ®Google Scholar
• Izquierdo, M.A., Scheffer, G.L., Flens, M.J., Shoemaker, R.H., Rome, L.H. and Scheper, R.J. (1996) “Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs”, Cytotechnology 19, 191–197.
   PubMed Web of Science ®Google Scholar
• List, A.F., Spier, C.S., Grogan, T.M., et al. (1996) “Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia”, Blood 87, 2464–2469.
   PubMed Web of Science ®Google Scholar
• Zaman, G.J.R., Flens, M.J., van Leusden, M.R., et al. (1994) “The human multidrug-resistance-associated protein MRP is a plasma membrane drug-efflux pump”, Proc. Natl. Acad. Sci. USA 91, 8822–8826.
   PubMed Web of Science ®Google Scholar
• Beck, W.T., Grogan, T.M., Willman, C.L., Cordon-Cardo, C., et al. (1996) “Methods to detect Pgp-associated multidrug resistance in patients' tumors: consensus recommendations”, Cancer Res. 56, 3010–3020.
   PubMed Web of Science ®Google Scholar
• Elsinga, P.H., Franssen, E.J.F., Hendrikse, N.H., et al. (1996) “[C-11]-labeled daunorubicin and verapamil for probing P-glycoprotein in tumours with PET”, J. Nucl. Med. 37, 1571–1575.
   PubMed Web of Science ®Google Scholar
• Goldstein, L.J., Galski, H., Fojo, A.T., Willington, M., Lai, S.L., et al. (1989) “Expression of a multidrug resistance gene in human cancers”, J. Natl. Cancer Inst. 81, 116–124.
   PubMed Web of Science ®Google Scholar
• Holmes, J., Jacops, A., Carter, G., Janowska-Wieczorek, A. and Padua, R.A. (1989) “Multidrug resistance in haematopoetic cell lines. Myelodysplastic syndromes and acute myelocytic leukemia”, Br. J. Haematol. 72, 40–44.
   PubMed Web of Science ®Google Scholar
• Nooter, K., Sonnevald, P., Oostrum, R.G., Herweijester, H., Hagenbeck, A. and Valerio, D. (1990) “Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A”, Int. J. Cancer 45, 263–268.
   PubMed Web of Science ®Google Scholar
• Herweijer, H., Sonnevald, P., Baas, F. and Nooter, K. (1990) “Expression of mdr1 and mdr3 multidrug resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine”, J. Natl. Cancer Inst. 82, 1133–1140.
   PubMed Web of Science ®Google Scholar
• Rothenberg, M.L., Mickley, L.A., Cole, D.E., Balis, F.M., Tsuruo, T., Poplock, D.G. and Fojo, A.T. (1989) “Expression of the mdr-1/P-170 gene in patients with acute lymphoblastic leukemia”, Blood 74, 1388–1395.
   PubMed Web of Science ®Google Scholar
• Shustik, C., Groulx, N. and Gros, P. (1991) “Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukemia (CLL)”, Br. J. Haematol. 70, 50–56.
   Google Scholar
• Grogan, T.M., Spier, C.M., Salmon, S.E., Matzner, M., Rybski, J., Weinstein, R.S., Scheper, R.J. and Dalton, W.S. (1993) “P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy”, Blood 81, 490–495.
   PubMed Web of Science ®Google Scholar
• Miller, T.P., Grogan, T.M., Dalton, W.S., Spier, C.M., Scheper, R.J. and Salmon, S.E. (1991) “P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil”, J. Clin. Oncol. 9, 17–24.
   PubMed Web of Science ®Google Scholar
• Chen, C.-J., Chin, J.E., Ueda, K., et al. (1986) “Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells”, Cell 47, 381–389.
   PubMed Web of Science ®Google Scholar
• Endicott, J.A. and Ling, V. (1989) “The biochemistry of P-glycoprotein mediated multidrug resistance”, Annu. Rev. Biochem. 58, 137–171.
   PubMed Web of Science ®Google Scholar
• van der Bliek, A.M. and Borst, P. (1989) “Multidrug resistance”, Adv. Cancer Res. 52, 165–203.
   PubMed Web of Science ®Google Scholar
• Shustik, C., Dalton, W. and Gros, P. (1995) “P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation”, Mil. Aspects Med. 16, 1–78.
   PubMed Web of Science ®Google Scholar
• Tidefelt, U., Liliemark, J., Gruber, A., et al. (2000) “P-glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia”, J. Clin. Oncol. 18, 1837–1844.
   PubMed Web of Science ®Google Scholar
• Wilson, B., Bates, S., Fojo, A., et al. (1995) “Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy”, J. Clin. Oncol. 13, 1995–2004.
   PubMed Web of Science ®Google Scholar
• Dalton, W.S., Grogan, T.M., Rybski, J.A., Scheper, R.J., Richter, L., Kailey, J., Broxterman, H.J., Pinedo, H.M. and Salmon, S.E. (1989) “Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation”, Blood 73, 747–752.
   PubMed Web of Science ®Google Scholar
• Beck, W.T. (1984) “Cellular pharmacology of Vinca alkaloid resistance and its circumvention”, Adv. Enzyme Regul. 22, 207–227.
   PubMedGoogle Scholar
• Beck, W.T. and Qian, X.D. (1992) “Photoaffinity substrates for P-glycoprotein”, Biochem. Pharmacol. 43, 89–93.
   PubMed Web of Science ®Google Scholar
• Gros, P., Croop, J. and Housman, D. (1986) “Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins”, Cell 47, 371–380.
   PubMed Web of Science ®Google Scholar
• Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D. and Fiere, D. (1992) “Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis”, Blood 79, 473–476.
   PubMed Web of Science ®Google Scholar
• te Boekhorst, P.A., de Leeuw, K., Schoester, M., Wittebol, S., Nooter, K., Hagemeijer, A., Lowenberg, B. and Sonneveld, P. (1993) “Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells”, Blood 82, 3157–3162.
   PubMed Web of Science ®Google Scholar
• Del Poeta, G., Stasi, R., Aronica, G., Venditti, A., Cox, M.C., Bruno, A., Buccisano, F., Masi, M., Tribalto, M., Amadori, S. and Papa, G. (1996) “Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia”, Blood 87, 1997–2004.
   PubMed Web of Science ®Google Scholar
• Ball, E.D., Lawrence, D., Malnar, M., Ciminelli, N., Mayer, R., WursterHill, D., Davey, F.R. and Bloomfield, C. D. (1990) “Correlation of CD34 and multi-drug resistance P170 with FAB and cytogenetics but not prognosis in acute myeloid leukemia (AML)”, Blood 76, 252a.
   Google Scholar
• Nussler, V., Pelka-Fleischer, R., Zwierzina, H., et al. (1994) “Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndromes—first experience with their reversal”, Ann. Hematol. 69, S25–S29.
   PubMed Web of Science ®Google Scholar
• Goasguen, J.E., Dossot, J.M., Fardel, O., Le Mee, F., Gall, E., Leblay, R., Leprise, P.Y., Chaperon, J. and Fauchet, R. (1993) “Expression of multidrug resistance-associated P-glycoprotein (P-170_ in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications”, Blood 81, 2394–2398.
   PubMed Web of Science ®Google Scholar
• El Rouby, S., Thomas, A., Costin, D., Rosenberg, C.R., Potmesil, M., Silber, R. and Newcomb, E.W. (1993) “p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression”, Blood 82, 3452–3459.
   PubMed Web of Science ®Google Scholar
• Ludescher, C., Hilbe, W., Eisterer, W., et al. (1993) “Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay”, J. Natl. Cancer Inst. 85, 1751–1758.
   PubMed Web of Science ®Google Scholar
• Sparrow, L.R., Hall, F.J., Siregar, H. and van der Weyden, M.B. (1993) “Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukemia and correlation with in vitro drug resistance”, Leuk. Res. 17, 941–947.
   PubMed Web of Science ®Google Scholar
• Cornelissen, J.J., Sonneveld, P. and Schoester, M. (1994) “MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents”, J. Clin. Oncol. 12, 115–119.
   PubMed Web of Science ®Google Scholar
• Lowe, S.W., Ruley, H.E., Jacks, T. and Housman, D.E. (1993) “p53 dependent apoptosis modulates the cytotoxicity of anticancer agents”, Cell 74, 957–967.
   PubMed Web of Science ®Google Scholar
• Thottassery, J.V., Zambetti, G.P., Arimori, K., et al. (1997) “p53 dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents”, Proc. Natl. Acad. Sci. USA 4, 11037–11042.
   Google Scholar
• Beck, W.T. and Dalton, W.S. (1997) “Mechanisms of drug resistance”, In: DeVita, V.T., Hellman, S. and Rosenberg, S.A., eds, Principles and Practice of Oncology (J.B. Lippincott Co., Philadelphia), pp. 498–512.
   Google Scholar
• Kaye, S.B. (1997) “Multidrug resistance in breast cancer—is the jury in yet?”, J. Natl. Cancer Inst. 89, 902–903.
   PubMedGoogle Scholar
• Linn, S.C., Honkoop, A.H., Hoekman, K., et al. (1996) “p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer”, Br. J. Cancer 74, 63–68.
   PubMed Web of Science ®Google Scholar
• Bodey, B., Bodey, Jr., B., Groger, Jr., A.M., et al. (1997) “Immunocytochemical detection of the p170 multidrug resistance (MDR) and the p53 tumor suppressor gene proteins in human breast cancer cells: clinical and therapeutical significance”, Anticancer Res. 17, 1311–1318.
   PubMed Web of Science ®Google Scholar
• Fujiwara, T., Grimm, E.A., Mukhopadhyay, T., et al. (1994) “Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of wild-type p53 gene”, Cancer Res. 54, 2287–2291.
   PubMed Web of Science ®Google Scholar
• Zaman, G.J.R., Flens, M.J., van Leusden, M.R., et al. (1994) “The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump”, Proc. Natl. Acad. Sci. USA 91, 8822–8826.
   PubMed Web of Science ®Google Scholar
• Cole, S.P.C., Bhardwaj, G., Gerlach, J.H., et al. (1992) “Overexpression of a transporter gene in a multidrug resistant human cancer cell line”, Science 258, 1650–1656.
   PubMed Web of Science ®Google Scholar
• Almquist, K.C., Loe, D.W., Hipfner, D.R., Mackie, J.E., Cole, S.P. and Deleney, S.P. (1995) “Characterization of the M® 190 000 multidrug resistance protein (MRP) in drug—selected and transfected human tumour cell”, Cancer Res. 55, 102–110.
   PubMed Web of Science ®Google Scholar
• Flens, M.J., Izquierdo, M.A., Schaffer, G.L., Fritz, J.M., Meijer, C.J., Scheper, R.J. and Zaman, G.J.R. (1994) “Immunohistochemical detection of the multidrug resistance-associated protein MRP in human multidrug resistant tumour cells by monoclonal antibodies”, Cancer Res. 54, 4556–4563.
   PubMed Web of Science ®Google Scholar
• Van Luyn, M.J.A., Muller, M., Renes, J., et al. (1998) “Transport of glutathione conjugates into secretory vesicles is mediated by the multidrug-resistance protein 1”, Int. J. Cancer 76, 55–62.
   PubMed Web of Science ®Google Scholar
• Leier, I., Jedlitschky, G., Bucholz, U., Cole, S.P., Deeley, R.G. and Keppler, D. (1994) “The MRP gene encodes an ATP-dependent export pump for leukotriene C$ and structurally related conjugates”, J. Biochem. Chem. 269, 27807–27810.
   Google Scholar
• Muller, M., Meijer, C., Zaman, G.J., Borst, P., Scheper, R.J., Mulder, N.H., de Vries, E.G.E. and Jansen, P.L.M. (1994) “Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport”, Proc. Natl. Acad. Sci. USA 91, 13033–13037.
   PubMed Web of Science ®Google Scholar
• Versantvoort, C.H.M., Broxterman, H.J., Bagrij, T., Scheper, R.J. and Twentyman, P.R. (1995) “Regulation by glutathione of drug transport in multidrug-resistant human lung cancer cell lines overexpressing multidrug resistance-associated protein”, Br. J. Cancer 72, 82–89.
   PubMed Web of Science ®Google Scholar
• Hendrikse, N.H., Franssen, E.J.F., van der Graaf, W.T.A., Meijer, C., Piers, D.A., Vaalburg, W. and de Vries, E.G.E. (1998) “Tc-99m-sesta Tc-99m-Sestamibi is a substrate for P-glycoprotein and the multidrug resistance associated protein”, Br. J. Cancer 71, 353–358.
   Google Scholar
• Hendrikse, N.H., Franssen, E.J.F., van der Graaf, W.T.A., Vaalburg, W. and de Vries, E.G.E. (1999) “Visualization of multidrug resistance in vivo”, Eur. J. Nucl. Med. 26, 283–293.
   PubMedGoogle Scholar
• Raviv, Y., Pollard, H.B., Bruggeman, E.P., Pastan, I. and Gottesman, M.M. (1990) “Photosensitized labeling of a functional multidrug transporter in living drug resistant tumor cells”, J. Biol. Chem. 265, 3975–3980.
   PubMed Web of Science ®Google Scholar
• Burger, H., Nooter, K., Zaman, G.J., Sonneveld, P., van Wingerden, K.E., Oostrum, R.G. and Stoter, G. (1994) “Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias”, Leukemia 8, 990–997.
   PubMed Web of Science ®Google Scholar
• Burger, H., Nooter, K., Sonneveld, P., Van Wingerden, K. E., Zaman, G.J. and Stoter, G. (1994) “High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia”, Br. J. Haematol. 88, 348–356.
   PubMed Web of Science ®Google Scholar
• Hart, S.M., Ganeshaguru, K., Hoffbrand, A.V., Prentice, H.G. and Mehta, A.B. (1994) “Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia”, Leukemia 8, 2163–2168.
   PubMed Web of Science ®Google Scholar
• McKenna, S.L., Whittaker, J.A., Padua, R.A. and Holmes, J.A. (1993) “Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia: drug sensitivity or resistance?”, Leukemia 7, 1199–1203.
   PubMed Web of Science ®Google Scholar
• Holmes, J., Wareing, C., Jacobs, A., Hayes, J.D., Padua, R.A. and Wolf, C.R. (1990) “Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data”, Br. J. Cancer 62, 209–212.
   PubMed Web of Science ®Google Scholar
• Johnston, J.B., Israels, L.G., Goldenberg, G.J., Anhalt, C.D., Verburg, L., Mowat, M.R. and Begleiter, A. (1990) “Glutathione S-transferase activity, sulfhydryl group and glutathione levels, and DNA cross-linking activity with chlorambucil in chronic lymphocytic leukemia”, J. Natl. Cancer Inst. 82, 776–779.
   PubMed Web of Science ®Google Scholar
• Pirker, R., Pohl, G., Stranzl, T., Suchomel, R.W., Scheper, R.J., Jager, U., Geissler, K., Lechner, K. and Filipits, M. (1999) “The lung resistance protein (LRP) predicts poor outcome in acute myeloid leukemia”, Adv. Exp. Med. Biol. (United States) 457, 133–139.
   Google Scholar
• Xu, D., Arestrom, I., Virtala, R., Pisa, P., Peterson, C. and Gruber, A. (1999) “High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone”, Br. J. Haematol. 106, 627–633.
   PubMed Web of Science ®Google Scholar
• Filipits, M., Pohl, G., Stranzl, T., Suchomel, R.W., Scheper, R.J., Jager, U., Geissler, K., Lechner, K. and Pirker, R. (1998) “Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia”, Blood 91, 1508–1513.
   PubMed Web of Science ®Google Scholar
• Filipits, M., Drach, J., Pohl, G., el al. (1999) “Expression of die lung resistance protein predicts poor outcome in patients with multiple myeloma”, Clin. Cancer Res. 5, 2426–2430.
   PubMed Web of Science ®Google Scholar
• Rimsza, L.M., Campbell, K., Dalton, W.S., Salmon, S., Willcox, G. and Grogan, T.M. (1999) “The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma”, Leuk. Lymphoma 34, 315–324.
   PubMed Web of Science ®Google Scholar
• Raaijmakers, H.G., Izquierdo, M.A., Lokhorst, H.M., et al. (1998) “Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma”, Blood 91, 1029–1036.
   PubMed Web of Science ®Google Scholar
• Den Boer, M.L., Pieters, R., Kazemier, K.M., Janka-Schaub, G.E., Henze, G. and Veerman, A.J. (1999) “Relationship between the intracellular daunorubicin concentration, expression of major vault protein/lung resistance protein and resistance to anthracyclines in childhood acute lymphoblastic leukemia”, Leukemia 13, 2023–2030.
   PubMed Web of Science ®Google Scholar
• Ogretmen, B., Barredo, J.C. and Safa, A.R. (2000) “Increased expression of lung resistance-related protein and multidrug resistance-associated protein messenger RNA in childhood acute lymphoblastic leukemia”, J. Pediatr. Hematol. Oncol. 22, 45–49.
   PubMed Web of Science ®Google Scholar
• Meijer, C., Mulder, N.H. and de Vries, E.G.E. (1990) “The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin”, Cancer Treat. Rev. 17, 389–407.
   PubMed Web of Science ®Google Scholar
• Moscow, J.A., Huang, H., Carter, C., et al. (1999) “Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy”, Blood 94, 52–61.
   PubMed Web of Science ®Google Scholar
• Hersdorffer, C., Ayello, J., Ward, M., et al. (1998) “Phase-1 trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation”, J. Clin. Oncol. 16, 165–172.
   PubMed Web of Science ®Google Scholar
• Kessel, D., Beck, W.T., Kukuruga, D. and Schulz, V. (1991) “Characterization of multidrug resistance by fluorescent dyes”, Cancer Res. 51, 4665–4670.
   PubMed Web of Science ®Google Scholar
• Charpin, C., Vielh, P., Duffaud, F., et al. (1994) “Quantitative immunocytochemical assays of Pgp in breast carcinomas: correlation to messenger RNA expression and to immunohistochemical prognostic indicators”, J. Natl. Cancer Inst. 86, 1539–1545.
   PubMed Web of Science ®Google Scholar
• van der Heyden, S., Gheuens, E., DeBruijn, E., Van Oosterom, A. and Maes, R. (1995) “Pgp: clinical significance and methods of analysis”, Crit. Rev. Clin. Lab. Sci. 32, 221–264.
   PubMed Web of Science ®Google Scholar
• Rabkin, D., Chieng, D.C., Miller, M.B., Jennings, T., Feustel, P., Steiniger, J. and Parnes, S.M. (1995) “Pgp expression in the squamous cell carcinoma of the tongue base”, Laryngoscope 105, 1294–1299.
   PubMed Web of Science ®Google Scholar
• Ambudkar, S.V., Lelong, J.H., Zhang, J., Cardarelli, C.O., Gottesman, M.M. and Pastan, I. (1992) “Partial purification and reconstitution of the human multidrug resistance pump: characterization of the drug-stimulatable ATO hydrolysis”, Proc. Natl. Acad. Sci. USA 89, 8472–8476.
   PubMed Web of Science ®Google Scholar
• Oda, Y., Schneider-Stock, R., Rys, J., Gruchala, A., Niezabitowski, A. and Roessner, A. (1996) “Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas”, Diagn. Mol. Pathol. 5, 98–106.
   PubMed Web of Science ®Google Scholar
• Charpin, C., Vielh, P., Duffaud, F., et al. (1994) “Quantitative immunocytochemical assays of Pgp in breast carcinomas: correlation to messenger RNA expression and immunohistochemical prognostic indicators”, J. Natl. Cancer Inst. 86, 1539–1545.
   PubMed Web of Science ®Google Scholar
• Melefors, O. and Hentze, M.W. (1993) “Translational regulation by mRNA/protein interactions in eucaryotic cells: ferritin and beyond”, Bioassays 15, 85–90.
   PubMed Web of Science ®Google Scholar
• Danielsson, R., Reihner, E., Grabowska, A. and Bone, B. (2000) “The role of scintimammography with 99mTc-Sestamibi as a complementary diagnostic technique in the detection of breast cancer”, Acta Radiol. 41, 441–445.
   PubMed Web of Science ®Google Scholar
• Wang, H., Maurea, S., Mainolfi, C., Fiore, F., Gravina, A., Panico, M.R., Bazzicalupo, L. and Salvatore, M. (1997) “Tc-99m MIBI scintigraphy in patients with lung cancer. Comparison with CT and fluorine-18 FDG PET imaging”, Clin. Nucl. Med. 22, 243–249.
   PubMed Web of Science ®Google Scholar
• Yokogami, K., Kawano, H., Moriyama, T., Uehara, H., Sameshima, T., Oku, T., Goya, T., Wakisaka, S., Nagamachi, S., Jinnouchi, S. and Tamura, S. (1998) “Application of SPET using technetium-99m Sestamibi in brain tumours and comparison with expression of the MDR-1 gene: is it possible to predict the response to chemotherapy in patients with gliomas by means of 99mTc-Sestamibi SPET?”, Eur. J. Nucl. Med. 25, 401–409.
   PubMedGoogle Scholar
• Piwnica-Worms, D., Krounage, J.F. and Chiu, M.L. (1990) “Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence”, Circulation 82, 1826–1838.
   PubMed Web of Science ®Google Scholar
• Kostakoglu, L., Elahi, N., Kiratli, P., et al. (1997) “Clinical validation of influence Pgp on the uptake of Tc-99m-SestaTc-99m-Sestamibi in patients with malignant tumors”, J. Nucl. Med. 38, 1003–1008.
   PubMed Web of Science ®Google Scholar
• Kostakoglu, L., Kiratli, P., Ruacan, S., et al. (1998) “Association of tumor wash-out rates and accumulation of Tc-99m-SestaTc-99m-Sestamibi with the expression of Pgp in lung cancer”, J. Nucl. Med. 39, 228–234.
   PubMed Web of Science ®Google Scholar
• Kostakoglu, L., Ruacan, S., Ergun, E.L., Hayran, M. and Bekdik, C.F. (1998) “Influence of the heterogeneity of P-glycoprotein expression on technetium-99m-MIBI uptake in breast cancer”, J. Nucl. Med. 39, 1021–1026.
   PubMed Web of Science ®Google Scholar
• Kostakoglu, L., Guc, D., Canpinar, H., et al. (1998) “P-glycoprotein expression by technetium-99m-MIBI scintigraphy in hematologic malignancy”, J. Nucl. Med. 39, 1191–1197.
   PubMed Web of Science ®Google Scholar
• Del Vecchio, S., Ciarmiello, A., Potena, M.I., et al. (1997) “In vivo detection of multi-drug resistant (MDR1) phenotype by technetium-99m Sestamibi scan in untreated breast cancer patients”, Eur. J. Nucl. Med. 24, 150–159.
   PubMedGoogle Scholar
• Duran Cordobes, M., Starzes, A., Delmon-Moingeon, L., et al. (1996) “Technetium-99m- uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression”, J. Nucl. Med. 37, 286–289.
   PubMed Web of Science ®Google Scholar
• Piwnica-Worms, D., Chiu, M.L., Budding, M., Kronauge, J.F., Kramer, R.A. and Croop, J.M. (1993) “Functional imaging of multidrug-resistant Pgp with an organotechnetium complex”, Cancer Res. 53, 977–984.
   PubMed Web of Science ®Google Scholar
• Rao, V.V., Chiu, M.L., Kronauge, J.F. and Piwnica-Worms, D. (1994) “Expression of recombinant human multidrug resistance Pgp in insect cells confers decreased accumulation of technetium-99m-sestaTc-99m-Sestamibi”, J. Nucl. Med. 35, 510–515.
   PubMed Web of Science ®Google Scholar
• Andrews, D.W., Das, R., Kim, S., Zhang, J. and Curtis, M. (1997) “Technetium Tc-99m-Sestamibi as a glioma imaging agent for the assessment of multidrug resistance”, Neurosurgery 40, 1323–1332.
   PubMed Web of Science ®Google Scholar
• Piwnica-Worms, D., Rao, V.V., Kronauge, J.F. and Croop, J.M. (1995) “Characterization of multidrug resistance P-glycoprotein function with an organotechnetium complex”, Biochemistry 34, 12210–12220.
   PubMed Web of Science ®Google Scholar
• Bailly, J.D., Muller, C., Jaffrezou, J.P., Demur, C., Gassar, G., Bordier, C. and Laurent, G. (1995) “Lack of correlation between expression and function of P-gly-coprotein in acute myeloid leukemia cell lines”, Leukemia 9, 799–807.
   PubMed Web of Science ®Google Scholar
• Kapucu, L.O., Akyuz, C., Vural, G., Oguz, A., Atasever, T., Buyukpamukcu, M. and Unlu, M. (1997) “Evaluation of therapy response in children with untreated malignant lymphomas using technetium-99m-Sestamibi”, J. Nucl. Med. 38, 243–247.
   PubMed Web of Science ®Google Scholar
• Gruber, A., Arestrom, I., Xu, D., Liliemark, J., Larsson, S.A. and Jacobsson, H. (1998) “Multidrug resistance phenotype in leukemic cells from patients with acute myelocytic leukemia can be detected with 99Tc(m)-Tc-99m-Sestamibi”, Br. J. Cancer, 77, 1732–1736.
   PubMed Web of Science ®Google Scholar
• Tirovola, E.B., Biassoni, L., Britton, K.E., Kaleva, N., Kouykin, V. and Malpas, J.S. (1996) “The use of 99mTc-Tc-99m-Sestamibi scanning in multiple myeloma”, Br. J. Cancer 74, 1815–1820.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulou-Strauss, A., Strauss, L.S., Goldschmidt, H., Lorenz, W.J., Maier-Borst, W. and van Kaick, G. (1995) “Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas”, Eur. J. Nucl. Med. 22, 434–442.
   PubMedGoogle Scholar
• Duran Cordobes, M., Moretti, J.L., de Veco, B., et al. (1997) “Tc 99m Sestamibi uptake in human cell lines exhibiting multidrug resistance related to MDR or MRP genes”, J. Nucl. Med. 38, 253.
   Web of Science ®Google Scholar
• Mansi, I., Rambaldi, P.F., La Provitera, A., Di Gregorio, F. and Procaccini, E. (1995) “Techneium-99m-tetrofosmin uptake in breast tumors”, J. Nucl. Med. 36, 83.
   Google Scholar
• Klain, N., Maurea, S., Lastoria, S., Cuocolo, A., Colao, A. and Salvatore, M. (1995) “Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer”, J. Nucl. Med. 36, 2248–2251.
   PubMed Web of Science ®Google Scholar
• Sun, S.S., Hsieh, J.F., Tsai, S.C., Ho, Y.J. and Kao, C.H. (2000) “Technetium-99m tetrofosmin mammoscintigraphy findings related to the expression of P-glycoprotein mediated multidrug resistance”, Anticancer Res. 20, 1467–1470.
   PubMed Web of Science ®Google Scholar
• Tabuenca, M.J., Vargas, J.A., Varela, A., Salas, C., Cajal, S.R., Durantez, A. and Berrocal, J.O. (1999) “Inverse correlation between Tc-99m-tetrofosmin uptake and P-glycoprotein in non-small cell lung cancer”, J. Nucl. Med. 40, 1224–1225.
   Web of Science ®Google Scholar
• Tabuenca, M.J., Vargas, J.A., Varela, A., Salas, C., Durantez, A. and Ortiz Berrocal, J. (1998) “Correlation between 99m Tc-tetrofosmin uptake and P-glycoprotein expression in non-small-cell lung cancer”, Rev. Esp. Med. Nucl. (Spain) 17(6), 427–434.
   Google Scholar
• Bae, K.T. and Piwnica-Worms, D. (1997) “Pharmacokinetic modeling of multidrug resistance P-glycoprotein transport of gamma-emitting substrates Q”, J. Nucl. Med. (Italy) 41(2), 101–110.
   Google Scholar
• Fukumoto, M., Yoshida, D., Hayase, N., Kurohara, A., Akagi, N. and Yoshida, S. (1999) “Scintigraphic prediction of resistance to radiation and chemotherapy in patients with lung carcinoma: technetium 99m-tetrofosmin and thallium-201 dual single photon emission computed tomography study”, Cancer (United States) 86(8), 1470–1479.
   Google Scholar
• Gros, P., Talbot, F., Tang-Wai, D., Bibi, E. and Kaback, H.R. (1992) “Lipophilic cations: a group of model substrates for multidrug-resistance transporer”, Biochemistry 31, 1992–1998.
   PubMed Web of Science ®Google Scholar
• Crankshaw, C.L., Marmion, M., Luker, G.D., Rao, V., Dahlheimer, J., Burleigh, D., Webb, E., Deutch, K.F. and Piwnica-Worms, D. (1998) “Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein”, J. Nucl. Med. 39, 77–86.
   PubMed Web of Science ®Google Scholar
• Ballinger, J.R., Bannerman, J., Boxen, I., Firby, P., Hartman, N.G. and Moore, M.J. (1996) “Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells”, J. Nucl. Med. 37, 1578–1582.
   PubMed Web of Science ®Google Scholar
• Mehta, B.M., Rosa, E., Biedler, J.L. and Larson, S.M. (1994) “In vivo uptake of [C-14]-colchicine for identification of tumor multidrug resistance”, J. Nucl. Med. 35, 1179–1184.
   PubMed Web of Science ®Google Scholar
• Mehta, B.M., Levchenko, A., Rosa, E., Kim, S.W., Winnick, S., Zhang, J.J., Kalaigian, H. and Larson, S.M. (1996) “Evaluation of [C-14]-colchicine biodistribution with whole body quantitative autoradiography in colchicine-sensitive and -resistant xenografts”, J. Nucl. Med. 37, 312–314.
   PubMed Web of Science ®Google Scholar
• Hunter, A.L. and Klaassen, C.D. (1975) “Biliary excretion of colchicine”, J. Pharmacol. Exp. Ther. 192, 605–617.
   PubMed Web of Science ®Google Scholar
• Hendrikse, N.H., de Vries, E.G., Eriks-Fluks, L., van der Graaf, W.T., Hospers, G.A., Willemsen, A.T., Vaalburg, W. and Franssen, E.J. (1999) “A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier”, Cancer Res. 59, 2411–2416.
   PubMed Web of Science ®Google Scholar
• Guhlman, A., Krauss, K., Oberdorfer, F., et al. (1995) “Noninvasive assessment of hepatobiliary and renal elimination of cysteinyl leukotrienes by positron emission tomography”, Hepatology 21, 1568–1575.
   PubMed Web of Science ®Google Scholar